Next-IO™ CD47 × CD19 Therapeutic Bispecific Antibody Program
Shirley, NY 11967, USA, New York, 11967
Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop CD47 × CD19 Dual-Targeting Fusion Protein program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership together. For any partners interested in our Next-IO™ programs, Creative Biolabs welcomes collaboration.
5 out of 5 from 1 reviews